We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 21% above its sector, the market expects faster growth.
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, along with its subsidiaries, primarily manufactures and markets traditional Chinese medicine, Western pharmaceuticals, and various healthcare products within the People's Republic of China. Its business activities are structured into two distinct divisions: Chinese Medicine and Western Medicine. The company's operations extend beyond its core offerings to include the production and distribution of Chinese, Western, and biological pharmaceutical items. It also engages in the wholesale and retail trade of medicines, biochemical pharmaceutical products, and everyday consumer goods, in addition to managing hospitals. Furthermore, Tianjin Pharmaceutical Da Ren Tang provides a comprehensive suite of services such as logistics, inventory management, equipment installation, and drug processing. It also offers pharmaceutical inspection, testing, and advisory services. In terms of its commercial model, the company supplies its proprietary branded medicinal products directly to wholesalers. Conversely, it acquires pharmaceuticals marketed under other brands from distributors, subsequently reselling these to other wholesale clients. Established in 1992 and based in Tianjin, People's Republic of China, the company was previously known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited before adopting its current name in May 2022.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 600329.SS and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
